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Abstract
Background: Genomics, transcriptomics and proteomics of glioblastoma multiforme (GBM) have recently emerged
as possible tools to discover therapeutic targets and biomarkers for new therapies including immunotherapy. It is
well known that macroscopically complete surgical excision, radiotherapy and chemotherapy have therapeutic
limitations to improve survival in these patients. In this study, we used a differential proteomic-based technique
(2D-Difference Gel Electrophoresis) coupled with matrix-assisted laser desorption/ionization-time of flight (MALDI-
TOF) mass spectrometry to identify proteins that may serve as brain tumor antigens in new therapeutic assays. Five
samples of patients presenting a GBM and five samples of microscopically normal brain tissues derived from brain
epileptic surgery specimen were labeled and run in 2D-PAGE (Two-Dimensional Polyacrylamide Gel Electrophoresis)
with an internal pool sample on each gel. Five gels were matched and compared with DIA (Difference In-gel
Analysis) software. Differential spots were picked, in-gel digested and peptide mass fingerprints were obtained.
Results: From 51 protein-spots significantly up-regulated in GBM samples, mass spectrometry (MS) identified
twenty-two proteins. The differential expression of a selected protein set was first validated by western-blotting,
then tested on large cohorts of GBM specimens and non-tumor tissues, using immunohistochemistry and real-time
RT-PCR.
Conclusions: Our results confirmed the importance of previously described proteins in glioma pathology and their
potential usefulness as biological markers but also revealed some new interesting targets for future therapies.
Introduction
Malignant gliomas are the most common human pri-
mary brain tumors, glioblastoma multiforme (GBM)
being the most aggressive and lethal form. Median sur-
vival of patients affected by GBM is around 15 months
and nearly 75% of them will die within 18 months fol-
lowing diagnosis [1] despite treatment combining com-
plete excision then chemo- and radiotherapy, pointing
to the need for non-conventional therapies. Research
has thus focused on specific strategies targeting intracel-
lular signaling pathways [2], specific surface molecules,
antiangiogenesis therapy [3], immunotherapy [4] and
combinatorial approaches. Many reports identifying
genes [5] and proteins which can be used to distinguish
between GBM and either other gliomas or non tumor-
ous brain tissue have increased our knowledge of this
pathology, but a combination of genomic, proteomic
and transcriptomic data will be needed to identify new
therapeutic targets or biomarkers.
Proteomic approaches were most widely based on
methods using differential expression on 2D-PAGE
gels [6] or, more recently, two dimensional chromato-
graphy [7] followed by mass spectrometry protein iden-
tification. The 2D-DIGE (two dimensional difference gel
electrophoresis) technology, using a mixed-sample inter-
nal standard, is now recognized as an accurate method
to determine and quantify human proteins, reducing
inter-gel variability and simplifying gel analysis. In the
present study, GBM (T) and non tumorous (Nt) brain
samples were labeled and fractionated using 2D-DIGE.
Mass fingerprints of differentially expressed proteins
were acquired with a MALDI-TOF/TOF spectrometer.
Western-blot experiments, or immunohistochemical
analysis for the largest series, were applied to confirm
the up-regulation of selected proteins. The relationship
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with mRNA expression of coding genes for some over
expressed proteins was analyzed by quantitative RT-
PCR.
Results
Detection and identification of differentially-expressed
proteins in GBM versus non-tumorous brain tissue
2D-DIGE was used to identify proteins differentially
expressed in GBM versus non tumorous samples. The
two-group experimental design (Figure 1A) using a
mixed internal standard enabled us to normalize spot
volumes from each sample, to perform inter-gel com-
parisons and to recognize statistically significant inter-
spot variations. A representative set of overlaid 2D-
DIGE images gels is given in Figure 1B.
On each analytical 2D gel, an average of 700 spots
corresponding to proteins with a pI between 3 and 10
and a molecular weight from 10 to 250 kDa was
detected and 457 spots were matched across the 5
gels. A total of 51 spots showed statistically significant
differences (Student’s t-test p-value ≤ 0.05) in protein
expression between the two populations with an aver-
age ratio > 2 and a statistical power of 0.88. These 51
spots were up-regulated in GBM. Only protein spots
on silver or Coomassie Blue-stained gels manually
matching with the corresponding DIGE images were
processed. Thirty protein-spots were identified, corre-
sponding to 22 different proteins (Table 1). This dis-
crepancy is explained by the fact that some proteins,
such as hemoglobin, DRP-2 (dihydropyrimidinase
related protein 2, or collapsin response mediator pro-
tein 2, CRMP-2) or ER-60 (Endoplasmic reticulum
resident protein 60 or protein disulfide-isomerase A3),
are found in several spots while in other circum-
stances two proteins can contribute to the same spot.
Results of DIGE analysis (average ratio glioblastoma/
normal brain tissue (GBM/NT), T-test), Mascot
search (matched peptides, % of coverage and Mascot
score) and protein characteristics (accession number,
theoretical Mt and pI) are listed for each protein in
Table 1.
GBM-overexpressed proteins included several blood
proteins. Tumors spots for hemoglobin, apolipoprotein
A1, serum albumin, and alpha-2 globulin were five
times larger than the same spots from non-tumorous
extracts.
Transthyretin was also four times more abundant in
GBM. Two members of the dihydropyrimidinase family,
DRP-2 and DRP-3 (or CRMP-4), were identified with an
average GBM/NT ratio of 6.5 and 4.29 respectively.
Three chaperone proteins HSP 27 (heat shock 27 kDa
protein), GRP-75 (75 kDa glucose-related protein or
heat-shock 70 kDa protein 9 also named mortalin), and
ER 60 were also over-expressed in GBM.
Some of the presently identified proteins have pre-
viously been described as brain tumor markers [8], i.e.
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
hemoglobin, tubulin beta, HSP 27, manganese superox-
ide dismutase Mn-SOD, vimentin, albumin, apolipopro-
tein A-1, ubiquitine carboxyl-terminal hydrolase L1
(UCH-L1) and glial fibrillary acid protein (GFAP), or
implicated in neurodegenerative diseases, i.e. UCH-L1 in
both Huntington’s and Parkinson’s diseases, apolipopro-
tein A-1 and DRP-2 in Alzheimer’s disease [8].
Validation of 2D-DIGE results by western blot analysis
To validate the results of the DIGE analysis, five pro-
teins, selected on the basis of interesting biological func-
tions and high-fold changes, were tested in western
blotting experiments with specific antibodies available
commercially, on tumor protein extracts from GBM and
control patients already used in 2D-DIGE. Equal amount
of proteins from each sample were loaded. As shown in
Figure 2, the expression levels for HSP 27 (29 kDa),
ALDH (aldehyde dehydrogenase, 50 kDa), and Mn-SOD
(20 kDa) were higher in GBM (n = 4 for Hsp27 and
ALDH and n = 6 for MnSOD) in comparison to their
expression in non-tumorous samples, thus confirming
the DIGE analysis.
Two bands (55 kDa and 65 kDa) were found for DRP-
2 and DRP-3. DRP-2 protein was expressed with a
strong signal at 55 kDa in GBM (n = 2) and a slight sig-
nal at 65 kDa while the contrary was seen for non-
tumorous samples. DRP-3 protein expression was also
different in GBM (n = 2) with a high signal at 65 kDa
and a slighter one at 55 kDa and non-tumorous samples
where no or faint bands could be found.
In situ validation of proteomic data by
immunohistochemistry
Immunohistochemical studies were carried out with the
five selected proteins already tested in western blot ana-
lysis, namely HSP 27, ALDH, Mn-SOD, DRP-2 and
DRP-3, revealed in 25 GBM and three non-tumoral
brain samples. The results confirmed their high expres-
sion in GBM. Figure 3 shows a representative paraffin-
embedded section and the respective non-tumorous
control for each protein. Immunohistochemical studies
gave the distribution of these proteins by cell category
of the normal parenchyma: astrocytes, oligodendrocytes,
neurons. All neurons (100%) were positive for ALDH,
Mn-SOD, DRP-2 and DRP-3 (Figure 4) except HSP 27
(0%). DRP-family molecules were strongly expressed in
normal astrocytes and oligodendrocytes (51% and 52%
positive cells respectively for DRP-2 and 68% and 75%
for DRP-3) however this expression was higher in GBM
cells (87% for DRP-2 and 88% for DRP-3). HSP 27 and
ALDH were also more expressed in GBM (68% and 69%
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respectively) than in astrocytes (17% and 7%) or oligo-
dendrocytes (23% and 2%).
mRNA expression analysis of genes corresponding to the
up-regulated proteins in GBM samples
Real-time RT-PCR assays on a series of 50 GBMs and
nine non-tumorous samples was performed to
examine the levels of transcript for HSP 27 (HSPB1),
MnSOD (SOD2), ALDH (ALDH2), DRP-2 (DPYSL2),
DRP-3 (DPYSL3) plus GRP-75(HSPA9) and UCHL-1
(UCHL1).
mRNA of frozen tissues was isolated and the amplifi-
cation of each selected genes, compared with GAPDH
amplification, was normalized via a pool of previously
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Figure 1 DIGE analysis on a series of 5 GBM samples (T) and 5 non tumorous samples (Nt). A) Experimental design. B) Examples of two
DIGE gels: a) Gel 1: the GBM sample (T6) was labeled with Cy5 Dye (red spots) and the control sample (Nt1) with Cy3 Dye (green spots). b) Gel
2: the GBM sample (T7) was labeled with Cy3 Dye (green spots) and control sample (Nt2) with Cy5 Dye (red spots). Merge spots appeared in
yellow. In all gels, internal standard was labeled with Cy-2 Dye (not visible in these images).
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used non-tumorous brain samples (or “control”) [9].
mRNA expression for GAPDH was identical for control
and GBM and none of the nine non-tumorous samples
tested against this control was considered as positive in
our study (data not shown).
UCH-L1 expression was not increased in the GBM
samples. ALDH, GRP-75 and DRP-2 disclosed mild
positivity with respectively 4%, 4% and 6% of the GBM
samples exhibiting an increase in mRNA expression
more than 2-fold greater than the reference. In contrast,
Table 1 Differentially expressed proteins in GBM samples identified by MALDI mass spectrometry after DIGE analysis*
Average ratio
GBM/NT(a)
T-test
(b)
Protein name Species Mt
Th.( c)
PI Th.
(d)
Accession
No. (gi) (e)
Matched
Peptides (f)
Coverage
% (g)
Score
(h)
7.33 0,0060 hemoglobin Homo
Sapiens
15834 6.76 61679606 11/82 80 100
6.52 0.0065 dihydropyrimidinase -related protein 2 Homo
Sapiens
62711 5.95 4503377 24/73 55 225
6.49 0,0058 apolipoprotein A-1 Homo
Sapiens
28061 5.27 90108666 17/69 50 153
6.47 0,035 human serum albumin Homo
Sapiens
67174 5.57 55669910 26/59 54 263
6.19 0,0078 alpha-2-globin Homo
Sapiens
15174 8.73 1335076 9/55 69 86
5.88 0.024 tubulin beta 2 Homo
Sapiens
50274 4.78 4507729 22/73 43 207
5.83 0,0015 ubiquitin carboxyl-terminal hydrolase
isozyme L1
Homo
Sapiens
25151 5.33 21361091 10/40 59 131
5.83 0,0022 ER-60 protease Homo
Sapiens
57160 5.98 1208427 17/40 34 170
4.60 0,0085 MTHSP75 (GRP-75) Homo
Sapiens
74019 5.9 292059 26/72 49 208
4.29 0.020 dihydropyrimidinase-related protein 3 Homo
Sapiens
62323 6.11 4503379 12/29 27 76
4.26 0,048 vimentin variant Homo
Sapiens
53708 5.06 62896523 25/100 59 172
higly similar to glial fibrillary acid protein
(GFAP)
Homo
Sapiens
49533 5.84 34536332 26/100 63 169
4.14 0,040 ACTB protein Homo
Sapiens
40536 5.55 15277503 12/57 45 93
4.02 0.050 transthyretin variants Homo
Sapiens
13806 5.57 2098255 10/42 81 153
3.59 0,049 human manganese superoxide dismutase
mutantQ143n (MnSOD)
Homo
Sapiens
22290 6.86 2780818 10/59 46 95
3.57 0,034 glyceraldehyde-3 phosphate
dehydrogenase
Homo
Sapiens
24776 8.68 89573929 8/39 47 89
3.32 0,021 heat shock protein 27 Homo
Sapiens
22427 7.83 662841 10/67 57 99
2.83 0,050 mitochondrial aldehyde dehydrogenase Homo
Sapiens
54394 5,6 6137677 17/71 43,3 134
2.76 0,037 tubulin alpha -1C Homo
Sapiens
50548 4.96 14389309 15/66 49 138
2.76 0,0084 tubulin alpha Homo
Sapiens
33321 5.86 37492 8/30 22 71
2.74 0,040 glutamate carboxypeptidase Homo
Sapiens
52700 5.7 15620780 14/40 38 143
2.57 0,024 LAP 3 protein (leucyl aminopeptidase) Homo
Sapiens
54724 6.80 37588925 15/46 38 149
* CyDye images were analyzed by BVA and spots that showed statistically significant differences (Student’s t-test) in intensity between the control and the GBM
groups are listed. (a) Average ratio GBM/NT: The average ratio value indicates the standardized volume ratio between the two groups: GBM and non tumorous
patients. A two-fold increase is represented by 2. (b) T-test: Student’s T-test p value: Only proteins with ratios showing significant differences (p£0.05) were
retained. (c):Mt th: Theoritical relative mass. (d) PI th: Theoritical isoelectric point. (e) GeneBank sequence identification number(f): Number of matched peptides
versus total number of peptides. (g): Percent coverage of the protein. (h) Mascot score: Protein scores greater than 81 are significant (p < 0.05).
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HSP 27, MnSOD and DRP-3 were clearly up-regulated
with respectively 32%, 44% and 46% of the GBM sam-
ples having a 5-fold increase in mRNA expression com-
pared with the pool of non-tumorous brain samples
(Figure 5).
Discussion
Extensive proteomic studies of human GBM have
emerged in the last decade allowing comparison
between GBM and normal brain proteomes and identi-
fication of differences in protein expression and pro-
files of diverse grades of gliomas (for review see
[6,10]).
The aim of the present proteomic work was to high-
light potential new glioblastoma tumor antigens thus
extending the number of proteins already used and
investigated, particularly in immunotherapy assays [9].
The 2D-DIGE technique was used to compare five
GBM and five non-tumorous brain samples. Differential
protein expression was analyzed by mass spectrometry.
2D-DIGE is a very powerful technique allowing controls
and experimental samples to be run on the same gel
together with an internal reference, each sample being
labeled with a different cyanine. Using the DeCyder soft-
ware, gel images can be analyzed to identify statistically
significant differences in protein expression between
        A) HSP 27 
                   B) ALDH 
                 C) Mn-SOD
D) DRP-2                                                                      E) DRP-3 
             T7                Nt3                T8                Nt2                                                         T8                Nt3                 T7              Nt2 
GBMs Non tumoral controls 
29 kDa 
50 kDa 
20 kDa 
T9           T8          T7              T6 
T9           T8        T7        T6 
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 Nt4       Nt3       Nt2        Nt1 
GBMs
GBMs
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 Nt4        Nt3             Nt2         Nt1 
65kDa 
55 kDa 
Figure 2 Selected proteins expression analyzed by western-blot. GBM (T) and non tumoral control (Nt) protein extracts were loaded on 1D
SDS-PAGE gels together with biotinylated molecular weight markers and transferred on Hybond-P membranes, then stained with primary and
secondary-HRP antibodies or Streptavidin-HRP. Immunoreaction was revealed using ECL. Protein expression was tested for HSP 27 (A), ALDH (B),
Mn-SOD (C), DRP-2 (D) and DRP-3 (E).
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A) HSP 27
E) DRP-3
D) DRP-2
C) Mn-SOD
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a) GBM b) NT control
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Figure 3 Selected proteins expression analyzed by immunohistochemistry. GBM (a) and non tumor control (b) paraffin-embedded sections
were stained with anti-HSP 27 (A), -ALDH (B), -Mn-SOD (C), -DRP-2 (D) and -DRP-3 (E) antibodies. Normal brain staining and one representative
sample are shown for each antigen. In control samples, the major cell types are indicated with arrows: the thickest arrows designate
oligodendrocytes, the intermediate arrows astrocytes and the narrow ones neurons. Magnifications for GBM samples were x 400 with a window
(I, II, III, IV,V) showing magnified small region (x 1000). Control samples were magnified x 1000.
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different samples on a limited number of gels [11]. This
technique is very useful for applications requiring accu-
rate quantization and direct differential proteomic analy-
sis of normal and abnormal tissues [12].
Twenty-two proteins were statistically highly
expressed in GBM comparatively to non-tumorous brain
samples. Some of them are involved in key metabolic
pathways and suspected to participate in tumorigenic
processes.
Blood and cytoskeletal proteins: two major groups up-
regulated in GBM
Blood proteins emerged as a significant group highlight-
ing the high angiogenesis capacity of GBM. GBM are
highly vascular tumours and this study analyzed the pro-
teome of the whole GBM sample extract, without
removing blood vessels. In a recent review [13], up-reg-
ulation of serum albumin and apolipoprotein-A1 were
commented as the consequence of the blood brain bar-
rier degradation in malignant gliomas. These results
reinforce previous reports describing hemoglobin [8],
apolipoprotein A-1 or albumin [8,14] as brain tumor
markers up-regulated in GBM.
Transthyretin (TTR), a plasma protein described as thyr-
oxin and retinol transporter, has recently gained interest in
neurobiology and seems to represent a key protein in ner-
vous system physiology [15]. Although TTR is synthesized
in the choroid plexus, there are several unclear points con-
cerning its other precise localizations and functions. In
cerebrospinal fluid, TTR levels are raised and lowered in
Parkinson’s and Alzheimer’s diseases respectively. Further-
more a physiological variant, transthyretin Thr119met
chain, is highly expressed in malignant areas of GBM [16].
The biological significance of this GBM-TTR overexpres-
sion and either its implication in gliomagenesis or its pos-
sible therapeutic role need further investigations.
Another significant class of differentially expressed pro-
teins is represented by cytoskeletal proteins: vimentin,
alpha (6,3) and beta (2) tubulin, beta actin and GFAP are
three- to six-fold increased in GBM. Beta-tubulins and
microtubule components are encoded by a multigene
family whose expression patterns are complex. In tumor
tissues, most isotypes exhibited an altered expression
which might represent markers of sensitivity for drug
response [17]. GFAP, a well-known specific astrocytic
marker, has been suggested as a serum diagnostic marker
for GBM [18]. It has been also disclosed in different
forms in high-grade gliomas (grade III and IV) but its
overexpression has been linked with the lower grade [19].
In the present work, GFAP was identified in three spots,
all of them being up-regulated in GBM.
Mitochondrial and endoplasmic reticulum proteins:
enzymatic and chaperone proteins involved in key
pathways and dysregulated in GBM
In eukaryotic cells, mitochondria and endoplasmic reti-
culum form two endomembrane networks which inter-
act closely with each other to control metabolic flow,
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Figure 4 In situ validation of the protein expression data obtained by immunohistochemistry. For each antibody, 1000 tumor cells were
counted and results were expressed as a percentage of positive cytoplasmic staining in two different and most expressive areas. Bars represent
standard deviation of results obtained with the 25 GBM and the three populations (astrocytes and oligodendrocytes and neurons) of 3 non-
tumorous samples (Nt samples). The expression of four proteins tested (HSP 27, ALDH, DRP-2, DRP-3) was higher in GBM cells than in normal
astrocyte or oligodendrocyte populations. All neurons were positive (100%) except for HSP 27 (0%).
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protein transport, intracellular signaling and cell death.
In normal glial cells, besides their essential role of ade-
nosine triphosphate (ATP) generation to produce
energy, mitochondria are also involved in the regulation
of cellular proliferation and apoptosis. The important
consequences of mitochondrial dysfunction in glioma in
these three areas was highlighted in a recent study [20].
It is not surprising to find some mitochondrial or endo-
plasmic reticulum proteins differentially expressed in
GBM and in non-tumorous samples. In the present
work, DIGE analysis and immunohistochemistry study
revealed that two mitochondrial enzymes, ALDH and
Mn-SOD, are highly expressed in GBM: on average in a
series of 50 GBM, 69% tumor cells were ALDH positive
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Figure 5 mRNA expression in 50 GBM samples analyzed by real-time RT-PCR. Results are expressed as the relative HSP 27 (A), Mn-SOD (B)
and DRP-3 (C) mRNA expression compared with the same pool of non-tumorous samples.
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and 81% Mn-SOD positive. RT-PCR analysis also
revealed a high level of transcripts encoding for
MnSOD. Mn-SOD expression has recently been sug-
gested as a potential GBM prognostic marker [21]
because the lack of overexpression is found in three
years survival group patients compared to short-term
survival patients. These results confirmed earlier work
which correlated shortest median survival with high
Mn-SOD enzyme expression level in GBM patients [22].
The second mitochondrial enzyme, ALDH, has not, to
our knowledge, been reported as a brain tumor marker,
but ALDH activity, detected commonly with ALDE-
FLUOR assay, has been used for identification and isola-
tion of adult stem cells and particularly neural stem
cells [23]. Cancer stem cells - or tumor initiating cells
(TICs)-, might be also identified in this way. Recently,
ALDH expression, characterized by immunohistochem-
ical staining of common epithelial cancers and their cor-
responding normal tissues, has been correlated with
ALDH enzymatic activity. In tumors for which corre-
sponding normal tissues expressed relatively low ALDH
levels (breast, lung, ovarian or colonic cancer), ALDH
can be proposed as a cancer stem cell marker [24].
Moreover, in breast and pancreatic cancers [25-27] the
presence of positive cells has been related with poor
survival, which was possibly explained by a greatest
resistance to chemotherapeutic drugs as demonstrated
for ovarian cancer cells [24]. In GBM, there is now
much evidence that such tumor stem cells exist and
despite several markers proposed for their identification
(CD133, SSEA-1 [28], A2B5 [29]), no consensus has
been reached. ALDH could therefore be a good candi-
date for best TIC enrichment in GBM.
GRP-75 (mortalin, MTHSP75), the mitochondrial cha-
perone Hsp70 kDa protein isoform 9, a major mitochon-
drial protein, plays a central role in protein import and
export. It could also localize in endoplasmic reticulum and
contribute to modulation of the stress response. GRP-75
was previously linked with malignant progression of low-
grade astrocytoma [30] and an increased expression of
these chaperones contribute to tumorigenesis [31]. Our
2D-DIGE analysis confirmed a higher expression in GBM
samples for GRP-75 and also two additional chaperone
proteins: the reticulum endoplasmic protein disulfite iso-
merase (ER-60, ERp57 or GRP-57) and the heat-shock
protein HSP 27. In brain, HSP 27 is linked with high-
grade gliomas [32] or high malignancy human glioma cell
line U87MG∆EGFR [33]. In cancer cells, HSP 27 is cur-
rently considered to participate in oncogenesis and in
resistance to chemotherapy [34]. Conversely, ER-60 was
previously reported as less expressed in GBM relatively to
low-grade astrocytomas [32,35], although its key role in
the control of newly synthesized glycoproteins during
oncogenic transformation has been recently assessed [36].
Additionally, ER-60 is involved in the modulation of
STAT-3 signaling and could contribute to a neoplastic dis-
eased state. These findings highlight the importance of
mitochondrial and reticulum endoplasmic proteins as tar-
gets for new therapies and suggest a particular study of
these organelles via specific proteome analysis. In a recent
paper, [13] a review of technical limitations in actual
glioma proteomics shows the interest of sub-proteomes
and particularly mitochondrial proteomes.
Dihydropyrimidinase proteins: importance of isoforms
Two dihydropyrimidinase proteins overexpressed in
GBM were selected and retained for validation experi-
ments by western blot, immunochemistry and RT-PCR
analysis. DRP-2 (CRMP-2/Ulip2) and DRP-3 (CRMP-4/
Ulip 1) are members of collapsing response mediator
proteins (CRMP) involved in regulation of neurite gui-
dance and synapse formation; they are highly expressed
during brain development and rarely in adult brains [37]
except DRP-2 which can be detected until adulthood in
several types of specialized neurons in the hippocampus,
cerebellum and dorsal root ganglion. CRMP family
members (DRP-1 to -5) have been essentially studied in
the context of neurodegenerative diseases [38-40] where
their expression is often altered. Nonetheless, some
reports respectively outlined DRP-2 [8] down-expression
and DRP-3 [14] up-regulation in GBM. In agreement
with the later, DRP-3 which was identified in 2D-gels in
only a single spot (65 kDa and 6.3 for MW and pI
respectively) was confirmed up-regulated by western
blot (65 kDa band), immunohistochemistry and RQ-
PCR analysis. It was not so obvious for DRP-2: DIGE-
study of GBM individualized four overexpressed spots:
two spots with an apparent mass of 65 kD and pI
around 5.9 and two acidic 55 kDa forms with 5.3 pI. In
western blots studies, a 65 kDa-DRP-2 was over
expressed in normal brain while in GBM it represented
a lighter isoform (55-60 kDa). RQ-PCR results revealed
that protein overexpression was not linked to a coding
gene up-regulation. In addition, immunochemistry,
which could not differentiate DRP-2 isoforms, confirmed
that 87% of GBM cells were positive compared to 51%
of astrocytes and 52% of oligodendrocytes in normal
brain. The DRP family is known to be highly phos-
phorylated [41,42]. Depending on study design and
experimental techniques, the molecular weight of phos-
phorylated or non- phosphorylated forms of DRP-2 has
been reported to vary from 55 kDa to 70 kDa [43,44].
Other post-translational modifications such as myristila-
tion, methylation or esterification can alter the pI of the
proteins, and glycosylation and prenylation can alter
their molecular weight [8]. In addition, some light forms
(55 kDa) could be breakdown products [45]. Our find-
ings revealed that DRP-2 was overexpressed in GBM,
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and that two isoforms could discriminate GBM from
non-tumorous brain tissue. Indeed, additional work is
necessary to analyze and determinate the nature of
translational modifications responsible for these iso-
forms and confirm the 55 KDa form as a potential
glioma marker.
In our study, we present five proteins that are also
regulated in neurodegenerative diseases: UCHL-1, trans-
htyretin, Apolipoprotein A1, DRP-2 and DRP-3. Altered
expression of these proteins in Alzheimer’s disease
(AD), Parkinson’s disease (PD) or Down Syndrome (DS)
may reflect their importance in brain physiology or may
be the result of stress generated by the disease. UCHL-1
is down-regulated in AD and in PD [46], transthyretin is
raised in PD, but lowered in AD. High levels of Apoli-
poprotein A1 were found to be associated with neurode-
generation in AD. Concerning DRP-family, DRP-2 was
increased in paired helical filaments and was related to
the loss of neurofibrillary tangles-free neurons in AD
([40]. In another work [38], DRP-2 was found down-
regulated at the mRNA level in DS and AD. In contrast,
at the proteomic level, an increased ratio of 55 kDa to
the 65 kDa forms in AD and DS brains suggested
decreased phosphorylation of the DRP-2 protein. Differ-
ential expression in spots for DRP-2 and DRP-3 was
reported in the study of R. Weitzdoerfer et al [39] in a
fetal DS brain analysis: increased levels of one spot
assigned to DRP-3 and decreased levels of spots
assigned to DRP-2. More studies about these proteins
and their isoforms would be necessary to conclude
about their use as markers in GBM.
Overall, this work underlines the up-regulation of sev-
eral GBM-related proteins; this was confirmed by wes-
tern blot and immunohistochemistry techniques in
some instances. These proteins might be attractive clini-
cal biomarkers, linked or not with survival, or a specific
GBM immunotherapy target. It could be also interesting
to explore specifically the mitochondrial or endoplasmic
reticulum GBM proteome which might open the way to
novel fields of therapeutic advances.
Materials and methods
Samples
GBM samples were obtained from patients admitted in the
Neurosurgery Department of Rennes University Hospital
and collected in accordance with the French regulations.
For the entire study, 66 patients were included, with
newly-diagnosed, untreated, primary glioblastoma (7 being
classified as giant cell glioblastoma,) and two patients with
a secondary glioblastoma. Twenty-three patients received
only radiotherapy after surgical resection, when 27
patients received radiotherapy with concomitant temozo-
lomide followed by adjuvant temozolomide (the current
standard treatment). Other patients were treated after
surgical resection with radiotherapy followed by different
chemotherapeutic regimens.
2D-DIGE and western blot analysis were conducted
on samples arising from five men (age range 43 - 72
years, mean: 60 years), classified as primary glioblas-
toma. The validation cohort for immunochemistry and
RT-PCR analysis was composed of 34 men and 30
women, (age range 35 - 75 years mean: 59 years). Some
patients were tested with both RT-PCR and immuno-
chemistry. Non-tumorous brain tissues were obtained
from normal areas (either grey or white matter) of brain
tissues removed from patients undergoing non-tumor
epileptic surgery. All samples were either conserved at
-80°C for 2D-DIGE, real time RT-PCR and western blot-
ting analysis, or formalin-fixed and paraffin-embedded
for immunohistochemistry.
Protein extraction
Cell lysates were prepared from five GBM and five non
tumorous brain samples by mechanical disruption in 2.5
volumes of ice-cold lysis buffer (Tris 20 mM, pH7.5,
CHAPS 4%, urea 8M (Sigma-Aldrich, St Louis, USA)
and antiproteases cocktail (Complete EDTA-free tablets,
Roche Diagnostics, Mannheim, Germany)). Samples
were sonicated (6 cycles of ten seconds with relapse of
30 seconds in ice-bath) and centrifuged (15 000 g, 30
minutes, 4°C). Supernatants were ultra centrifuged at
108,000 g for 60 minutes at 4°C. Protein concentration,
in the resulting supernatants containing cytosolic pro-
tein extracts, was determined using the Bradford protein
assay. Aliquots (100 μg) were conserved at -80°C.
Protein labeling with cyanin dyes
Cytosolic extracts were labeled with CyDyes DIGE
Fluors developed for fluorescence 2-D DIGE technology
(GE Healthcare, Bucks, UK) according to the manufac-
turer’s recommended protocol. Briefly, 50 μg of each
sample were minimally labeled with 400 pmol of amine-
reactive cyanine dyes, Cy3 or Cy5, on ice for 30 min-
utes, in the dark. GBM and non-tumorous samples were
labeled with Cy5 or Cy3 in a random manner to avoid
dye-specific protein labeling, as described in Figure 1A.
An internal pool, labeled with Cy2 fluorescent dye, was
generated by combining equal amounts of all cell cyto-
solic extracts and was included in all the gels run in this
study. The labeling reaction was quenched by incuba-
tion, for 10 minutes with 1 μL of 10 mM lysine (Sigma-
Aldrich, ST Louis, USA) on ice, in a darkroom.
Following the labeling reaction, GBM extracts and
their random non-tumorous tissue counterparts were
combined together with the internal pool, and Des-
treak™ IEF buffer (GE Healthcare) was added to make
up the volume to 450 μl prior to IEF (isoelectric focali-
sation) on five 24 cm gel strips.
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Two-dimensional SDS-PAGE
A first focusing isolectric electrophoresis was carried out
on IPGphor™ system (GE Healthcare). Pre-cast immobi-
lized pH gradient strips (pH 3-10 NL, 24 cm) were used
for this first-dimensional separation for a total focusing
time of 60 kV-h. After IEF, the IPG strips were incubated
two times under ambient temperature, for 15 minutes in
an equilibration solution (0.05M Tris-HCl pH 8.8, 6M
Urea, 30% glycerol, 2% SDS and bromophenol blue) con-
taining 65 mM DTT and 250 mM iodoacetamide respec-
tively. Strips were directly applied on top of pre-cast 12%
SDS-PAGE gels (GE Healthcare) and run in a vertical
Ettan DaltSix system (GE Healthcare) for approximately
5 hours. Five gels were processed simultaneously.
Gel imaging and data analysis
After SDS-PAGE, cyanine-labeled proteins were directly
visualized using a Typhoon™ 9400 imager scan (GE
Healthcare) in fluorescence mode. Cy2 images were
scanned using a 488 nm laser and an emission filter of
520 nm. Cy3 images were scanned using a 532 nm laser
and an emission filter of 580 nm. Cy5 images were
scanned using a 633 nm laser and an emission filter of
670 nm. Each gel was scanned at 200 μm (pixel size)
resolution and was processed using the DeCyder soft-
ware V5.01 (GE Healthcare) allowing quantification, gel
matching and statistical analyses.
The Differential In-gel Analysis module (DIA) was
used for pair-wise comparison of the two samples (GBM
and non-tumorous sample) on each gel, to exclude arti-
facts from gel images and differentially quantify the pro-
tein spots in the image. The Biological Variation
Analysis module (BVA) was used to match the entire
set of protein-spot maps from comparable gels simulta-
neously. Student’s test (p < 0.05) was used for statistical
analyses. Only spots with at least 2-fold changes in
volume after normalization samples were defined as
down- or up- regulated. The statistical power of the
analysis was calculated similarly to Karp N. et al [47]
and Engelen K. et al [48]. The standard deviation of the
log10 (standardized abundance) per condition was calcu-
lated for each spots that have been matched across the
5 gels of the analysis. The median of these standard
deviations was calculated in each condition to estimate
the global variance of the replicates. The statistical
power was then calculated for each condition using a
tool available online (http://udel.edu/~mcdonald/statt-
test.html[49]), for a 2-fold change (effect size = 0.301),
alpha = 0.05 and 5 replicates per group. After 2D-DIGE
imaging and analysis, gels were post-stained with silver-
stain [50] or Coomassie-blue. Gels were scanned (Image
Scanner TM GE Healthcare) and stored in 1% acetic
acid at 4°C until spot excision. Matching between silver-
or Coomassie-blue stained gels and fluorescence
maps was performed manually and pick lists were gen-
erated using the Image Master™ 2D Elite software (GE
Healthcare).
Protein identification by mass spectrometry
Silver-stained or Coomassie Blue-stained protein spots
were excised from 2-D gels and processed using an
Ettan™ Spot Handling Workstation (GE Healthcare).
Gel plugs were washed 3 times in MilliQ water, once in
50% methanol/50 mM ammonium bicarbonate and once
in 75% ACN to ensure complete removal of dye and
detergent. After drying, gel pieces were re-hydrated for
60 minutes with 8.3 μg/ml (Silver-stained gels) or 16.6
μg/ml (Coomassie-blue stained gels) sequencing grade
modified porcine trypsin (Promega, Charbonnières-les-
bains, France) in 20 mM NH4HCO3. Extraction was
performed in two successive steps by addition of 50%
ACN and 0.1% TFA. Digests were dried out and dis-
solved in 2 mg/mL a-cyano-4-hydroxycinnamic acid in
70% ACN/0.1% TFA, before spotting onto MALDI tar-
gets (384 Scout MTP 600 μm AnchorChip™; Bruker
Daltonics, GmbH, Bremen, Germany).
Peptide Mass fingerprints were acquired using a
MALDI-ToF/ToF mass spectrometer (Ultraflex™; Bruker
Daltonics, GmbH) and processed using the FlexAnalysis™
software (version 2.2; Bruker Daltonics, GmbH) for peak
list generation and a first internal calibration with trypsin
autodigestion peptides. Peak lists were then transferred to
ProteinScape™ software (version 1.3; Bruker Daltonics,
GmbH) for another automatic calibration based on a cali-
bration list (related to the sample type and treatment) con-
taining autolysis peaks and contaminants (keratins,
polymers and background peaks). After re-calibration, an
automatic trypsin and contaminants filtering and removal
was performed in order to submit only m/z related to the
sample and to obtain higher identification rates (Score-
Booster). Only the monoisotopic masses of tryptic pep-
tides were then used to query NCBInr sequence databases
(May 2008, 6493741 sequences) using the Mascot search
algorithm (Mascot server version 2.1.04; http://www.
matrixscience.com). Search conditions were as follows:
initial rather open mass window of 70 ppm for an internal
calibration, one missed cleavage allowed, modification of
cysteines by iodoacetamide and methionine oxidation as
variable modifications. Results were scored using the prob-
ability-based Mowse score (the protein score is -10 × log
(P) were P is the probability that the observed match is a
random event. In our conditions, a score greater than 81
indicated a significant identification (p < 0.05).
Immunochemical validation of overexpression of selected
proteins by western blotting
Cytosolic protein extracts (10-20 μg) were loaded on
12% polyacrylamide gels for 1D-SDS-PAGE together
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with biotinylated ECL western blotting molecular weight
markers (Amersham-GE-Healthcare) and then electro-
transferred on PVDF Hybond-P membrane (Amersham
Biosciences). Equal amount of proteins (quantified by
Bradford protein assay) for GBM and non tumorous
samples were loaded on each gel and the good quality
of transfer was visually verified with Red Ponceau stain-
ing of the membrane [51]. Non-specific sites were
blocked in Tris-buffered saline (TBS) containing 5% (w/
v) non-fat dry milk and blots were incubated with
diluted primary antibodies in 0.1% Tween 20, 1% non-
fat dry milk TBS. After washing in TBS, blots were incu-
bated with peroxidase-conjugated secondary antibodies
(Santa Cruz) diluted to 1/5000° in 1% non-fat dry milk
TBS or Streptavidin-HRP for biotinylated markers.
Immunoreaction was revealed using the enhanced che-
miluminescence system ECL+ (GE Healthcare). Dilu-
tions of specific primary antibodies were 1/200° for goat
polyclonal anti-human HSP 27 (C-20), DRP-2/CRMP-2
(D-17), DRP-3/CRMP-4 (V-17). Concentrations of poly-
clonal anti-human ALDH1 (goat, Calbiochem) and Mn-
SOD (rabbit, DD17, Sigma) were 2 μg/ml and 1.8 μg/ml
respectively.
Immunohistochemical procedure
Immunohistochemistry was performed on formalin-fixed
and paraffin-embedded tissues, using 5-μm sections
mounted on silanized slides. Antigen retrieval was per-
formed using citrate buffer (pH 6.0) at 80°C Bain-marie
(40 min) for DRP-3. The sections were incubated
respectively at 20° for 30 and 60 minutes with diluted
primary antibodies against HSP 27 and DRP-2 and over-
night at 4°C with antibodies against DRP-3, ALDH, Mn-
SOD (dilutions of 1:200, 1:25, 1:50, 1:200 and 1:800 for
respectively HSP 27, DRP-2, DRP-3, ALDH, and Mn-
SOD in antibody diluent of the Dako Cytomation Kit
(Trappes, France)). A second incubation (60 minutes)
with an anti-goat or anti-rabbit antibody (dilution 1:200,
DAKO Cytomation) was followed by a peroxidase-stain-
ing procedure using the RTU Vectastain Elite ABC kit
(Vector). Sections were counterstained with hematoxy-
lin-eosin-safran. Microscopic analysis was performed
using a Leitz-Diaplan microscope (Nuremberg, Ger-
many). Negative controls were obtained in the absence
of primary antibody. External positive controls were
used for each staining: normal breast for HSP 27; den-
date gyrus for DRP-2 and DRP-3; spleen for ALDH and
myocard for Mn-SOD. A total of twenty- five GBM and
three non-tumorous brain sampling were analyzed. For
each antibody, 1000 tumor cells were counted and
results were expressed as the percentage of cells with
positive cytoplasmic staining in two different and most
expressive analyzed areas.
Quantification of gene expression by real-time RT-PCR
Total RNA was extracted from frozen tissues samples:
50 GBM and 9 non-tumorous brain as previously
described [9]. In brief, sections of tumor samples, free
of necrotic areas, were processed with the Rneasy
Plus mini kit (Qiagen, Courtaboeuf, France). cDNA
was prepared from 0.5 μg purified RNA (High Capa-
city cDNA Reverse transcription kit, Applied Biosys-
tems, Courtaboeuf, France). Real-time-PCR was
performed with a spectrofluorometric thermal cycler
(ABI prism 7900, Applied Biosystems), following the
manufacturer’s recommendations. Primers and probes
for HSP 27 (HSPB1), DRP-2 (DPYSL2), DRP-3
(DPYSL3), ALDH (ALDH2), MnSOD (SOD2),UCHL-1
(UCHL1) and GRP-75 (HSPA9) genes were purchased
from Applied Biosystems (Assays-on-demand). Each
point of data was run in duplicate. To normalize the
data, GAPDH was chosen as an endogenous control.
The comparative Ct method was used to determine
relative gene copy numbers using the formula 2-∆∆Ct
with a pool of non-neoplastic brain samples as
reference.
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